ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVI

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是由国立卫生研究院、国家过敏和传染病研究所艾滋病分部主办的成人艾滋病临床试验小组的多中心试验。这项研究将比较三种不同的抗艾滋病毒药物方案作为首次治疗艾滋病毒感染的方法。目前抗HIV药物有一到三类：非核苷类似物、核苷类似物和蛋白酶抑制剂。这项研究中的三种方案中的每一种都使用两类抗HIV药物的药物，但没有使用第三类药物。每种方案都节省了一种不同类别的抗艾滋病毒药物。这项研究将考察这三种药物方案的有效性和安全性，以及这些方案的耐受性。这项研究还将考察这三种抗艾滋病毒药物对受试者新陈代谢变化的影响，因为接受艾滋病毒治疗的人有时会出现高血糖，血液中脂肪(如甘油三酯和胆固醇)水平高于正常水平，手臂和腿部脂肪减少，或身体其他部位如上背部和腹部脂肪增加。GCRC将被要求对同意参与这项试验的受试者进行DEXA扫描。受试者将在研究开始时、第48周和第96周接受DEXA扫描。如果受试者在研究过程中需要更换抗艾滋病毒方案，或者如果他们过早地停止了研究，他们将接受DEXA扫描。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center trial of the Adult AIDS Clinical Trial Group sponsored by the National Institutes of Health, National Institute of Alergy and Infectious Diseases, Division of AIDS. This study will compare three different anti-HIV drug regimens as first-time treatments for HIV infection. Currently anti-HIV drugs are from one to three classes: non-nucleoside analogues, nucleoside analogues and protease inhibitors. Each of the three regimens in this study use medication from two anti-HIV drug classes but spares a third class. Each regimen spares a different class of anti-HIV drug. This study will look at the effectiveness and safety of the three drug regimens and how well these regimens are tolerated. The study will also look at the effect of these three anti-HIV regiments on changes in the changes in the subjects' metabolism because people treated for HIV sometimes develop high blood sugar, higher than normal levels of fats (such as triglycerides and cholesterol) in their blood, loss of fat in the arms and legs, or increased fat in other parts of the body such as the upper back and abdomen. The GCRC will be asked to perform DEXA scans on the subjects who agree to participate in this trial. Subjects will recieve DEXA scans at study entry, week 48 and week 96. Subjects will receive DEXA scans if they need to switch anti-HIV regimens during the course of the study or if they discontinue the study prematurely.